M-MDSCs were classified in the PBMCs of healthy controls (HCs) and MS patients as CD33+HLA-DR−/lowCD14+CD15−-cells (Fig. 7a; gating strategy shown in Suppl Fig. 4) [2]. The gene discussed is CD33; the disease is myeloid sarcoma.